GERMANTOWN, Md., Dec. 15 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation (Nasdaq: AVNC - News), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA), for its once-daily Amoxicillin PULSYS product for the treatment of adolescents and adults with pharyngitis/tonsillitis (commonly referred to as strep throat) via the 505(b)(2) regulatory pathway.
